Should I buy or sell Alector stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ALEC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALEC, but not buy additional shares or sell existing shares. View ALEC analyst ratings or view top-rated stocks .

What is Alector's stock price target for 2024?

9 brokers have issued 1 year price objectives for Alector's stock. Their ALEC share price targets range from $4.00 to $41.00. On average, they anticipate the company's share price to reach $13.70 in the next twelve months. This suggests a possible upside of 123.9% from the stock's current price. View analysts price targets for ALEC or view top-rated stocks among Wall Street analysts .

How have ALEC shares performed in 2023?

Alector's stock was trading at $9.23 at the start of the year. Since then, ALEC shares have decreased by 33.7% and is now trading at $6.12. View the best growth stocks for 2023 here .

Are investors shorting Alector?

Alector saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 7,150,000 shares, a decrease of 6.9% from the October 31st total of 7,680,000 shares. Based on an average daily trading volume, of 717,100 shares, the short-interest ratio is currently 10.0 days. Approximately 11.7% of the shares of the stock are sold short. View Alector's Short Interest .

When is Alector's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our ALEC earnings forecast .

How were Alector's earnings last quarter?

Alector, Inc. (NASDAQ:ALEC) issued its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.12. The business had revenue of $9.11 million for the quarter, compared to analysts' expectations of $9 million. Alector had a negative net margin of 146.80% and a negative trailing twelve-month return on equity of 74.78%.

What ETF holds Alector's stock ?

iShares Neuroscience and Healthcare ETF holds 7,557 shares of ALEC stock, representing 1.22% of its portfolio.

What is Arnon Rosenthal's approval rating as Alector's CEO?

4 employees have rated Alector Chief Executive Officer Arnon Rosenthal on Glassdoor.com . Arnon Rosenthal has an approval rating of 100% among the company's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alector own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT) , NVIDIA (NVDA) , Pfizer (PFE) , Advanced Micro Devices (AMD) , Gossamer Bio (GOSS) , Kaleido Biosciences (KLDO) , QUALCOMM (QCOM) , Intel (INTC) , Micron Technology (MU) and Cisco Systems (CSCO) .

When did Alector IPO?

(ALEC) raised $177 million in an initial public offering on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO.

Who are Alector's major shareholders?

Alector's stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (14.47%), Braidwell LP (4.84%), Morgan Stanley (3.97%), JPMorgan Chase & Co. (2.72%), Euclidean Capital LLC (1.55%) and Jacobs Levy Equity Management Inc. (0.92%). Insiders that own company stock include Arnon Rosenthal , Calvin Yu , Gary Romano, Marc Grasso, Polaris Venture Management Co, Richard H Scheller , Robert King , Robert Paul , Sara Kenkare-Mitra and Shehnaaz Suliman . View institutional ownership trends .

How do I buy shares of Alector?

Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Does Alector have any subsidiaries?

The following companies are subsidiares of Alector: Alector LLC. Read More

Alector Stock Price, News & Analysis (NASDAQ:ALEC)

$6.12

+0.32 (+5.52%)

(As of 12/8/2023 ET)

Compare

Today's Range: $5.65
▼
$6.39
50-Day Range: $3.77
▼
$6.68
52-Week Range: $3.66
▼
$9.86

Volume: 668,308 shs
Average Volume: 593,985 shs
Market Capitalization: $514.91 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.70

Alector MarketRank™ Stock Analysis

Analyst Rating: Hold
2.44 Rating Score
Upside/Downside: 123.9% Upside
$13.70 Price Target
Short Interest: Bearish
11.68% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.92
Upright™ Environmental Score
News Sentiment: -0.72
Based on 4 Articles This Week
Insider Trading: Selling Shares
$3.19 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.78) to ($2.33) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

443rd out of 954 stocks

Biological Products, Except Diagnostic Industry

50th out of 128 stocks

3.2

Analyst's Opinion

Consensus Rating
Alector has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 5 buy ratings, 3 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $13.70, Alector has a forecasted upside of 123.9% from its current price of $6.12.
Amount of Analyst Coverage
Alector has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
11.68% of the float of Alector has been sold short.
Short Interest Ratio / Days to Cover
Alector has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.
Change versus previous month
Short interest in Alector has recently decreased by 6.90%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Alector does not currently pay a dividend.
Dividend Growth
Alector does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Alector has received a 70.25% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for diseases with neurocognitive impairment" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Alector is -0.92.

1.3

News and Social Media Coverage

News Sentiment
Alector has a news sentiment score of -0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Alector this week, compared to 1 article on an average week.
Search Interest
1 people have searched for ALEC on MarketBeat in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Alector insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,185,926.00 in company stock.
Percentage Held by Insiders
14.00% of the stock of Alector is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
69.71% of the stock of Alector is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Alector are expected to decrease in the coming year, from ($1.78) to ($2.33) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Alector is -3.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Alector is -3.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Alector has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Alector Stock (NASDAQ:ALEC)

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its pipeline products include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001, AL002, and AL101 to treat neurodegenerative diseases. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

ALEC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ALEC Stock News Headlines

December 1, 2023 | marketbeat.com

These biotechs targeting multiple neurodegenerative diseases (ALEC)

A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market.

December 8, 2023 | markets.businessinsider.com

Hold Rating on Alector Amid Potential for AL002 in Alzheimer’s, Caution Advised Pending Clinical Data

December 8, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 8, 2023 | markets.businessinsider.com

Buy Rating on Alector: Advancements in Neuro Pipeline, Operational Efficiency, and Anticipated Catalysts Drive Positive Outlook

November 8, 2023 | finanznachrichten.de

Alector, Inc.: Alector Reports Third Quarter 2023 Financial Results and Provides Business Update

November 8, 2023 | finance.yahoo.com

Alector to Participate in the Stifel Healthcare Conference

November 7, 2023 | chron.com

Alector: Q3 Earnings Snapshot

November 7, 2023 | finance.yahoo.com

Alector Reports Third Quarter 2023 Financial Results and Provides Business Update

December 8, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

October 27, 2023 | msn.com

Alector achieves target enrollment for Phase 3 dementia study

October 5, 2023 | markets.businessinsider.com

Alector’s Financial Stability and Promising Clinical Developments: An Analyst’s Hold Rating Rationale

October 4, 2023 | msn.com

Alector: Milestone Uncertainty Plus Lack Of Product Revenue

September 25, 2023 | msn.com

Alector slips as Goldman Sachs starts at Sell on risk to lead programs

September 25, 2023 | msn.com

High Tide, Alector among healthcare movers

September 23, 2023 | msn.com

Cantor Fitzgerald Initiates Coverage of Alector (ALEC) with Overweight Recommendation

September 22, 2023 | benzinga.com

Analyst Expectations for Alector's Future

September 9, 2023 | seekingalpha.com

Alector completes enrollments in mid-stage Alzheimer’s trial

September 8, 2023 | msn.com

Alector completes enrolment in AL002 trial to treat early Alzheimer’s

August 31, 2023 | msn.com

Alector (ALEC) Price Target Increased by 30.49% to 15.59

August 12, 2023 | msn.com

Mizuho Maintains Alector (ALEC) Buy Recommendation

August 10, 2023 | markets.businessinsider.com

Alector (ALEC) Receives a Buy from Mizuho Securities

August 9, 2023 | msn.com

Stifel Maintains Alector (ALEC) Hold Recommendation

August 8, 2023 | msn.com

Morgan Stanley Reiterates Alector (ALEC) Equal-Weight Recommendation

August 5, 2023 | msn.com

HC Wainwright & Co. Reiterates Alector (ALEC) Buy Recommendation

August 4, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Alector (ALEC)

August 4, 2023 | marketwatch.com

Alector Up 31% After 2Q Results, Drug Program Update

July 27, 2023 | finance.yahoo.com

Alector to Host Mid-Year Earnings Conference Call

See More Headlines

Receive ALEC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/08/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ALEC
CUSIP: N/A
CIK: 1653087
Web: www.alector.com
Phone: (415) 231-5660
Fax: N/A
Employees: 246
Year Founded: 2013

Price Target and Rating

Average Stock Price Target: $13.70
High Stock Price Target: $41.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +123.9%
Consensus Rating: Hold
Rating Score (0-4): 2.44
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.69)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-133,310,000.00
Net Margins: -146.80%
Pretax Margin: -142.37%
Return on Equity: -74.78%
Return on Assets: -19.39%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.95
Quick Ratio: 3.95

Sales & Book Value

Annual Sales: $96.31 million
Price / Sales: 5.35
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.59 per share
Price / Book: 2.36

Miscellaneous

Outstanding Shares: 84,136,000
Free Float: 72,357,000
Market Cap: $514.91 million
Optionable: Not Optionable
Beta: 0.69

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Arnon Rosenthal Ph.D. (Age 67)
Co-Founder, CEO & Director
Comp: $1.02M
Dr. Sara Kenkare-Mitra Ph.D. (Age 55)
President and Head of Research & Development
Comp: $1.19M
Dr. Marc Grasso M.D. (Age 50)
CFO, Principal Financial Officer & Principal Accounting Officer
Comp: $738.05k
Dr. Gary Romano M.D. (Age 61)
Ph.D., Chief Medical Officer
Comp: $602.98k
Mr. Peter Heutink Ph.D.
Chief Scientific Officer
Katie Hogan
Senior Director of Corporate Communication & Investor Relations
Ms. Danielle Pasqualone J.D.
Ph.D., General Counsel
Ms. Clare Hunt M.B.A.
Chief People Officer
Ms. Kristina Cutter M.P.H.
Chief Regulatory, Pharmacovigilance, & Quality Assurance Officer
Ms. Virginia DeJesus-Rueff M.B.A.
Chief of Staff & Head of Strategy

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALEC Stock Analysis - Frequently Asked Questions

Should I buy or sell Alector stock right now?: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ALEC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALEC, but not buy additional shares or sell existing shares.
View ALEC analyst ratings or view top-rated stocks.
What is Alector's stock price target for 2024?: 9 brokers have issued 1 year price objectives for Alector's stock. Their ALEC share price targets range from $4.00 to $41.00. On average, they anticipate the company's share price to reach $13.70 in the next twelve months. This suggests a possible upside of 123.9% from the stock's current price.
View analysts price targets for ALEC or view top-rated stocks among Wall Street analysts.
How have ALEC shares performed in 2023?: Alector's stock was trading at $9.23 at the start of the year. Since then, ALEC shares have decreased by 33.7% and is now trading at $6.12.
View the best growth stocks for 2023 here.
Are investors shorting Alector?: Alector saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 7,150,000 shares, a decrease of 6.9% from the October 31st total of 7,680,000 shares. Based on an average daily trading volume, of 717,100 shares, the short-interest ratio is currently 10.0 days. Approximately 11.7% of the shares of the stock are sold short.
View Alector's Short Interest.
When is Alector's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our ALEC earnings forecast.
How were Alector's earnings last quarter?: Alector, Inc. (NASDAQ:ALEC) issued its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.12. The business had revenue of $9.11 million for the quarter, compared to analysts' expectations of $9 million. Alector had a negative net margin of 146.80% and a negative trailing twelve-month return on equity of 74.78%.
What ETF holds Alector's stock ?: iShares Neuroscience and Healthcare ETF holds 7,557 shares of ALEC stock, representing 1.22% of its portfolio.

What is Arnon Rosenthal's approval rating as Alector's CEO?: 4 employees have rated Alector Chief Executive Officer Arnon Rosenthal on Glassdoor.com. Arnon Rosenthal has an approval rating of 100% among the company's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Alector own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Intel (INTC), Micron Technology (MU) and Cisco Systems (CSCO).
When did Alector IPO?: (ALEC) raised $177 million in an initial public offering on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO.
Who are Alector's major shareholders?: Alector's stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (14.47%), Braidwell LP (4.84%), Morgan Stanley (3.97%), JPMorgan Chase & Co. (2.72%), Euclidean Capital LLC (1.55%) and Jacobs Levy Equity Management Inc. (0.92%). Insiders that own company stock include Arnon Rosenthal, Calvin Yu, Gary Romano, Marc Grasso, Polaris Venture Management Co, Richard H Scheller, Robert King, Robert Paul, Sara Kenkare-Mitra and Shehnaaz Suliman.
View institutional ownership trends.
How do I buy shares of Alector?: Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
Does Alector have any subsidiaries?: The following companies are subsidiares of Alector: Alector LLC.
Read More

This page (NASDAQ:ALEC) was last updated on 12/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial